Intravoxel incoherent motion diffusion-weighted MRI of infiltrated marrow for predicting overall survival in newly diagnosed acute myeloid leukemia
J Li, W Li, J Niu, X Song, W Wu, T Gong, R Zheng… - Radiology, 2020 - pubs.rsna.org
Background Acute myeloid leukemia (AML) features relatively low overall survival (OS).
Intravoxel incoherent motion (IVIM) diffusion-weighted MRI separates tissue microcapillary …
Intravoxel incoherent motion (IVIM) diffusion-weighted MRI separates tissue microcapillary …
Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia
L Xu, D Yao, J Tan, Z He, Z Yu, J Chen, G Luo… - Journal of Hematology & …, 2018 - Springer
Stem cell memory T (T SCM) and central memory T (T CM) cells can rapidly differentiate into
effector memory (T EM) and terminal effector (T EF) T cells, and have the most potential for …
effector memory (T EM) and terminal effector (T EF) T cells, and have the most potential for …
Immune-based therapeutic strategies for acute myeloid leukemia
M Böhme, S Kayser - Cancers, 2021 - mdpi.com
Simple Summary This review summarizes various therapeutic immune approaches
representing their targets, the efficacy and toxicity in the treatment of acute myeloid …
representing their targets, the efficacy and toxicity in the treatment of acute myeloid …
Shifting paradigms in the treatment of older adults with AML
TW LeBlanc, HP Erba - Seminars in Hematology, 2019 - Elsevier
The treatment of acute myeloid leukemia has been associated with dismal outcomes despite
available therapies. The morbidity and mortality associated with acute myeloid leukemia …
available therapies. The morbidity and mortality associated with acute myeloid leukemia …
Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines
RSS Illangeswaran, DZP Jebanesan, KK Sivakumar… - Leukemia Research, 2023 - Elsevier
Chemotherapy resistance leading to disease relapse is a significant barrier in treating acute
myeloid leukemia (AML). Metabolic adaptations have been shown to contribute to therapy …
myeloid leukemia (AML). Metabolic adaptations have been shown to contribute to therapy …
High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia
H Senjo, M Onozawa, D Hidaka, S Yokoyama… - Scientific reports, 2022 - nature.com
Acute myeloid leukemia (AML) patients older than 65 years have a poor prognosis.
Recently, CAR (C-reactive-protein/albumin ratio) has been actively reported as a prognostic …
Recently, CAR (C-reactive-protein/albumin ratio) has been actively reported as a prognostic …
[HTML][HTML] Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual …
BS Cho, SA Yahng, GJ Min, S Park, SS Park… - … and Cellular Therapy, 2021 - Elsevier
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most effective
postremission therapy conferring the chance of cure for acute myeloid leukemia (AML) …
postremission therapy conferring the chance of cure for acute myeloid leukemia (AML) …
Low‐dose thymoglobulin for prevention of chronic graft‐versus‐host disease in transplantation from an HLA‐matched sibling donor
Despite the proven efficacy of anti‐T‐cell or antithymocyte globulin (ATG) for chronic graft‐
versus‐host disease (GVHD) prevention in transplantation from an unrelated donor, dosing …
versus‐host disease (GVHD) prevention in transplantation from an unrelated donor, dosing …
FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis
S Li, N Li, Y Chen, Z Zheng, Y Guo - Frontiers in Oncology, 2023 - frontiersin.org
Background Fms-like tyrosine kinase 3 (FLT3) gene mutations occur in approximately 30%
of all patients with acute myeloid leukemia (AML). Internal tandem duplication (ITD) in the …
of all patients with acute myeloid leukemia (AML). Internal tandem duplication (ITD) in the …
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
T Takahashi, K Usuki, K Matsue, H Ohno… - International Journal of …, 2019 - Springer
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations in patients
with acute myeloid leukemia (AML) are associated with early relapse and poor survival. This …
with acute myeloid leukemia (AML) are associated with early relapse and poor survival. This …